Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients

Inclusion Criteria: * Diagnosis of transfusion-dependent Thalassemia being followed by a thalassemia comprehensive care clinic Age 18 or older * Taking deferasirox and on a stable dose for \>3 months * Evidence on cardiac MRI of mild to moderate cardiac iron overload (T2\*\<20ms but ≥10ms) as measured within 3 months prior to randomization. If a recent cardiac MRI has not been obtained, patients who otherwise meet all eligibility criteria and provide appropriate consent will undergo a cardiac MRI to confirm eligibility * Preserved left ventricular ejection fraction (LVEF) \>55% as measured by cardiac MRI. If a recent cardiac MRI has not been obtained, patients who otherwise meet all eligibility criteria and provide appropriate consent will undergo a cardiac MRI to confirm eligibility. * Agreeable to use an approved method of contraception if female of childbearing potential for the entire duration of the study. Exclusion Criteria: * Serum ferritin \< 500 ng/mL at screening * Liver iron concentration \> 30 mg/g dw as measured by liver R2 MRI (FerriScan) * Congestive heart failure * Severe refractory Hypotension (less than 90 mmHg systolic) * Currently taking any calcium channel blockers * Pregnancy or nursing (a negative HCG (pregnancy) test must be obtained prior to randomization) * As a result of medical review, physical examination or screening investigations, the Principal Investigator (PI) considers the subject unfit for the study * No fixed address * Hypersensitivity …